Member Info for nursesteve

The timing of this mornings RNS and the placing price obviously took the wind out of many investors sails and is gutting as far as my highest top up price (13.5p) goes. But trying to look beyond the disappointing features in this action by the BoD. It does provide funds for the development of collaborative work on a very relevant marketable product and remembering the potential here I’ve sold my MICRO shares when they were up 25% this morning and added here. Promising myself not going to add anymore (and definitely not advice to anyone else) but I’ve brought my average down and will hold hoping soon to see much more positive news in the next RNS. GLA

Ponsonby - thank you for your input. We have our expert!

Twisty if you look on page 9 it states
“ Once the Nuvec® vaccine particle reaches the target, such as an antigen-presenting cells, the particle is internalised into the cell via a process known as endocytosis. This encapsulates the Nuvec® complex into a membrane-bound vesicle known as an endosome. The endosome has a more acidic pH level than observed in blood vessels. This pH change causes the PEI to change charge and the silica spikes to disintegrate. This releases PEI, which ruptures the endosome and releases the DNA/RNA payload into the cell cytoplasm. Depending on whether the payload is DNA or RNA-based determines the next step. If the payload is DNA-based, the nucleic acid is delivered to the nucleus, the part of the cell which carries most of the genetic information. Once in the nucleus, the pDNA is transcribed into mRNA, which is released into the cytoplasm and translated into the protein antigen.”

To me it seems the delivery system that has been proven would deliver RNA or DNA into cell cytoplasm but I admit I’m no scientist.

Looking at that release the company seems make no difference in delivering RNA or DNA.

Lol no expert expru! I did look at montyboz post on Sunday that had the following link https://www.n4pharma.com/wp-content/uploads/2020/11/2020_SP_Angel_N4P_Initiation_Note_FINAL.pdf

Hi Twisty, Good to see you here. Thanks again for the steer towards RR - I doubled there.
Just seen your posts on here. I am no expert on the differences in RNA and DNA but based my decision on the company’s released RNS that directly mentioned the use to cold chain RNA vaccine manufacturers.

This is why I think a collaboration will be announced soon. N4P have solved the logistic problem of DNA RNA cold chain storage of COVID vaccines. This isn’t just a problem for third world countries that will all need to be vaccinated (as can be seen from care homes having to be supplied via hospital hubs that have the cold chain storage). If those COVID vaccine manufacturers (Pfizer and Moderna) that currently need ultra-cold chain storage don’t collaborate with N4P soon then other vaccines that are innovated after those will be used that don’t require ultra-cold storage will take over the market because they will be cheaper and easier to transport and store. It’s in these manufacturers best interests!

Figgy I was lucky on Amigo as my stop loss kicked in and I had averaged down so left with profit. I have bought back since so leaving a small stake of 30,000 shares as a pure long term gamble, it all depends on the upheld complaints and the current BoD inspire much more confidence. That was a great chat board though, so nice to see a few from there in other shares I now hold.

Morning Figgy. Holding & topped up a few times. Today being the latest. First in at just over 7p highest top up 13.5p very confident that this will rocket.

Heartily agree with FTH. Brighty Mazik MrJango Expru etc all very informative and their input greatly appreciated.

Figgy always good to read your posts. GLA

Market conditions problem, solution and demand are all almost in alignment the next RNS should be the aligned signed FIRST collaboration. As the RNS states N4P Demonstrating that Nuvec® loaded with a plasmid DNA can be dried, stored at convenient temperatures and reconstituted without any drop in transfection is a significant step forward in our formulation development work.

"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines. However, it also highlights that these vaccines have certain limitations, in that they often require extreme storage conditions.“

GLA

Having topped up this morning at 13.5p (and no it wasn’t my £39k buy earlier), I am slightly frustrated by today’s drop. However I believe N4P should come good as they solve a cold chain problem that is not only relevant for some current COVID vaccinations but also for other applications. As Van Tam would say multiple shots on goal! GLA

It’s always nice to see some old Amigo’s ;-)

After top slicing yesterday I’ll look to top up today.

Must admit it was too tempting for me so I’ve top sliced locking in some of my gains. Might have been better putting a stop loss in place though as I think it does have great potential, I just don’t trust the MM. GLA.

Not cross ramping just explaining. I was looking at this RNS https://www.londonstockexchange.com/news-article/N4P/formulation-work-update/14778519 Regarding solving ultra cold transport of vaccinations.

My apologies- wrong board.

Potentially explosive RNS! Timing is everything

Brought my average down to 96p a share - still happy. Wish I had some more funds available to add - and more shares in DDDD! GLA